| (Values in U.S. Thousands) | Mar, 2023 | Mar, 2022 | Mar, 2021 | Mar, 2020 | Mar, 2019 |
| Sales | 0 | 0 | 7,360 | 7,510 | 7,270 |
| Sales Growth | unch | -100.00% | -2.00% | +3.30% | +9.49% |
| Net Income | -14,730 | -19,990 | -19,930 | -14,540 | -9,770 |
| Net Income Growth | +26.31% | -0.30% | -37.07% | -48.82% | -68.45% |
Antibe Therapeutics Inc (ATBPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Antibe Therapeutics Inc. is a biotech company with a drug platform of therapeutics in pain and inflammation. Its lead drug candidate consists of ATB-346, non-addictive drug for chronic pain and inflammation; ATB-352, for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. Antibe Therapeutics Inc. is based in Toronto, Canada.
Fiscal Year End Date: 03/31